The Estradiol Patch for Women With Clot Risk
Of all the differences between routes of estrogen, this is the one with the most evidence behind it and the most consequence. Estrogen swallowed goes through the liver first and changes the way the blood clots. Estrogen through the skin does not. For most women that is a nuance. For a specific group it is the whole decision.
The patch page explains why the route matters in general. This page is for the woman who has a reason to care about clots specifically.
Why the route changes the risk
Anything swallowed is absorbed from the gut into the portal vein and delivered to the liver at high concentration before it reaches the rest of the body. Estrogen arriving that way prompts the liver to make more of several clotting factors and less of the proteins that restrain clotting. The blood becomes, measurably, more ready to clot.
Estrogen absorbed through the skin enters the general circulation directly, at the steady, lower concentrations the liver sees from a woman's own ovaries. The clotting-factor shift largely does not happen.
The clinical evidence lines up with the mechanism. The Women's Health Initiative, using oral estrogen, found venous thromboembolism roughly doubled. The French ESTHER study and later large observational analyzes found that transdermal estrogen carried no measurable increase in clot risk compared with no treatment, while oral estrogen carried the increase the WHI had shown. No randomized trial has compared the two routes head-to-head on clots, and it is unlikely one will, but the consistency of the observational data is why the Menopause Society and others recommend transdermal estrogen for women at elevated clot risk.
Stroke follows a similar, if less complete, pattern: the excess seen with oral estrogen in older women appears attenuated or absent with transdermal use at standard strengths.
Who this decides the route for
A previous clot. A woman with a history of deep vein thrombosis or pulmonary embolism — provoked or unprovoked — is generally not offered oral estrogen. Whether she can use a patch depends on the circumstances of the clot, whether she is anticoagulated, and hematology input. It is often possible; it is never automatic.
A thrombophilia. Factor V Leiden, prothrombin gene mutation, protein C or S deficiency. For carriers who have never had a clot, transdermal estrogen appears not to add meaningfully to their baseline risk, where oral estrogen multiplies it. This is one of the clearest cases for the patch.
Obesity. Excess weight is itself a clot risk, and oral estrogen compounds it. For a woman with a BMI over 30, the patch is the default route in most guidance.
Smoking. Same logic. We would rather she stopped, and we will say so, but the route decision does not wait for that.
Other risks. Immobility, recent surgery, active cancer, and some autoimmune conditions. Each is a conversation, not a rule.
Who is still excluded
The patch reduces a risk; it does not abolish the category. An acute clot, an active cancer that is estrogen-sensitive, a recent stroke or heart attack, and a known clotting disorder that has already produced events despite anticoagulation are situations in which systemic estrogen of any route is generally not offered. In those cases the honest answer is a local product for local symptoms — vaginal estrogen, which is barely absorbed — and non-hormonal options for the rest.
We also want the history before the prescription, not after. A "minor" clot in a leg after a long flight fifteen years ago is a relevant fact, and the assessment asks for it.
Progesterone and clots
The estrogen route is most of the story; the progestogen is the rest. Synthetic progestins, particularly medroxyprogesterone acetate, appear to add to clot risk. Micronized progesterone does not, on the available evidence. A woman on a patch for clot reasons should be on micronized progesterone rather than a progestin, and at ACT 2 she is.
Frequently asked questions
On the evidence, transdermal estrogen does not increase clot risk over no treatment. Oral estrogen roughly doubles it. The difference is due to first-pass metabolism in the liver, which the patch bypasses.
Sometimes. It depends on why the clot happened, whether you are anticoagulated, and specialist input. Oral estrogen is generally not offered; the patch may be.
For carriers who have never had a clot, transdermal estrogen appears not to add meaningfully to baseline risk, where oral estrogen multiplies it. It is one of the strongest cases for choosing the patch.
The excess stroke risk seen with oral estrogen in older women appears attenuated or absent with transdermal use at standard strengths. The evidence is less complete than for venous clots.
Synthetic progestins appear to add to it; micronized progesterone does not, on the available evidence.
Discuss it with the clinician managing your surgery. For long-haul travel, transdermal estrogen is not usually a reason to stop; the ordinary precautions — movement, hydration — apply.
Where this fits in your plan
The Estradiol Patch page covers the product; the women's HRT page covers how a plan is built. A baseline panel and a full clotting history come first — and if the history is complicated, so does a hematologist.
We measure first. Then we act.
References
- Canonico M et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840–845.
- Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 2019;364:k4810.
- Rossouw JE et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women (WHI). JAMA 2002;288:321–333.
- The Menopause Society. The 2022 Hormone Therapy Position Statement. Menopause 2022;29:767–794.
- Renoux C et al. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010;340:c2519.
- Straczek C et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 2005;112:3495–3500.
- Back toEstradiol Patch
- Estradiol patch or pillThe route matters more than most people expect. What changes when estradiol bypasses the liver, and why guidance increasingly favors transdermal.Read
- Estradiol and breast cancer riskThe boxed warning is gone; the question is not. What the WHI actually found for estrogen alone versus combined therapy, in absolute numbers, and what it means for you.Read
How we write and review our content
ACT 2 Health provides clinician-led care. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. This content is educational and is not medical advice. Individual results vary.
Compounded medication. Prepared by a licensed compounding pharmacy under a prescription written for you. Compounded medications are not FDA-approved, are not reviewed by the FDA for safety or effectiveness, and are not equivalent to or interchangeable with any branded product. Prescribed only when a licensed provider determines it is medically appropriate.
Care is delivered via telemedicine by healthcare professionals licensed in the state where the patient is located. Services are available only in states where our providers are licensed.
If you have symptoms of a blood clot — a swollen, painful leg, sudden breathlessness or chest pain — seek emergency care.